Since the initiation of the Human Metabolome Project in 2005, the metabolomics technique has gathered significant attention from the industry stakeholders. It is worth mentioning that about 40,000 small molecules constitute the human metabolome. Further, 30% of the known genetic disorders are associated with small-molecule metabolism. Therefore, metabolome profiling can assist in obtaining a better understanding of the disease. The approach has also demonstrated to be capable of identifying new biomarkers (for diagnosis and prognosis) and novel drug targets. In fact, 50% of the total drug candidates are reported to emanate from pre-existing metabolites. Integration of metabolomics with development projects holds the potential to significantly improve the efficiency and success rate of drug discovery, owing to its ability to differentiate promising candidates in the early stages. As a result, metabolomics has become an indispensable part of modern drug discovery and development process and disease diagnosis. Further, with the growing prominence of personalized medicine, there is an increased demand for rapid, highly sensitive and accurate quantification methods, such as metabolomics, to analyze clinical specimens. It is worth highlighting that various types of metabolite detection techniques, including targeted metabolomics and untargeted metabolomics, are being employed for diagnosis, severity determination and therapy development efforts against COVID-19. Specifically, studies have reported the potential implications of the serum metabolome in understanding the pathophysiology of the aforementioned disease.
Given the growing pipeline of biomarkers and drug discovery projects, the current demand for metabolite profiling is high. In this context, more than 18,000 drug candidates are being evaluated across different development stages, at present. Although some pharmaceutical companies have established in-house metabolomics research capabilities, significant capital investments and specialized requirements render this approach prohibitive for most stakeholders. Moreover, the associated metabolomics technologies, including chromatography and spectrometry, are complicated by multi-step analytical protocols and technically demanding expertise, which eventually leads to contamination of samples and lack of reproducibility in test results. This has created a demand for service providers having the required expertise in the global metabolomics market. In fact, since 2000, more than 70 players offering metabolomics services have been established. Amidst growing competition in the metabolomics services market, the implementation of cutting-edge tools and technologies, such as artificial intelligence, big data analytics, deep learning, machine learning and quantum computing, serves to differentiate the offerings of stakeholders. Hence, several service providers engaged in this upcoming market have actively begun expanding their respective service portfolios, either through undertaking strategic acquisitions or forming alliances with other specialty companies. Considering the ongoing advancements and active research efforts, the metabolomics services market size is anticipated to be quadruple in the foreseen future.
The “Metabolomics Services Market by Area of Application (Biomarker Discovery, Personalized Medicine, Disease Diagnostics, Drug Discovery and Toxicological Testing), Type of Metabolomics Service(s) Offered (Targeted Metabolomics and Untargeted Metabolomics), Type of Metabolome Profiling Techniques Used (LC-MS, GC-MS and NMR), Type of End User (Research / Academic Institutes, Pharma / Biotech Firms and CROs) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and future potential of the metabolomics services market. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in providing metabolomics services.
Given the growing pipeline of biomarkers and drug discovery projects, the current demand for metabolite profiling is high. In this context, more than 18,000 drug candidates are being evaluated across different development stages, at present. Although some pharmaceutical companies have established in-house metabolomics research capabilities, significant capital investments and specialized requirements render this approach prohibitive for most stakeholders. Moreover, the associated metabolomics technologies, including chromatography and spectrometry, are complicated by multi-step analytical protocols and technically demanding expertise, which eventually leads to contamination of samples and lack of reproducibility in test results. This has created a demand for service providers having the required expertise in the global metabolomics market. In fact, since 2000, more than 70 players offering metabolomics services have been established. Amidst growing competition in the metabolomics services market, the implementation of cutting-edge tools and technologies, such as artificial intelligence, big data analytics, deep learning, machine learning and quantum computing, serves to differentiate the offerings of stakeholders. Hence, several service providers engaged in this upcoming market have actively begun expanding their respective service portfolios, either through undertaking strategic acquisitions or forming alliances with other specialty companies. Considering the ongoing advancements and active research efforts, the metabolomics services market size is anticipated to be quadruple in the foreseen future.
Scope of the Report
The “Metabolomics Services Market by Area of Application (Biomarker Discovery, Personalized Medicine, Disease Diagnostics, Drug Discovery and Toxicological Testing), Type of Metabolomics Service(s) Offered (Targeted Metabolomics and Untargeted Metabolomics), Type of Metabolome Profiling Techniques Used (LC-MS, GC-MS and NMR), Type of End User (Research / Academic Institutes, Pharma / Biotech Firms and CROs) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and future potential of the metabolomics services market. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in providing metabolomics services.
Amongst other elements, the report features:
- A detailed review of the overall landscape of companies offering metabolomics services to various organizations, including research / academic institutes, pharma / biotech firms and CROs, along with analysis based on various relevant parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters. The chapter also provides details related to pre-profiling service(s) offered (experiment design and sample preparation), metabolomics service(s) offered (targeted metabolomics, untargeted metabolomics and unknown metabolite identification), additional services offered (lipidomics, metabolic flux analysis, proteomics, and xenobiotic metabolites analysis), type of metabolome profiling technique used (mass spectrometry, nuclear magnetic resonance, liquid chromatography, gas chromatography, inductively coupled plasma spectroscopy, capillary electrophoresis), type of approach used for data analysis (multivariate analysis, univariate analysis, preprocess and normalization, clustering analysis, enrichment analysis and classification and feature selection), type of biological sample analyzed (biological fluids, tissues, cells and stool), source of biological sample (animal, microbe, human and plant) and area of application (biomarker discovery, disease diagnostics, drug discovery, toxicological testing and personalized medicine).
- An in-depth analysis, highlighting the contemporary market trends, using eight schematic representations, including [A] waffle chart representations (based on regional distribution of various industry and non-industry players), [B] world map representations (based on the country-wise distribution of various industry and non-industry players), [C] a horizontally stacked bar chart representation (based on company / organization size and type of service provider), [D] a mekko chart representation (based on area of application and company / organization size), [E] a vertically stacked bar chart representation (based on type of metabolome profiling technique used and type of biological sample analyzed), [F] a tree map representation (based on type of metabolome profiling technique and area of application), [G] a 4D bubble analysis comparing the key players engaged in this domain, based on several relevant parameters (such as year of establishment, number of metabolomics services offered, company / organization size and region), [H] a grid representation (based on company / organization size, region, type of metabolomics services offered, type of metabolome profiling technique used and area of application).
- An in-depth company competitiveness analysis of metabolomics service providers, segmented into four categories, namely large and very large (>500 employees), mid-sized (51-500 employees), small (11-50 employees) and very small companies (<10 employees). Within the peer group, companies were ranked based on various relevant parameters, such as supplier power (based on the experience) and portfolio strength (based on parameters, such as number of pre-profiling profiling services offered, number of additional services offered, type of metabolome profiling technique used, type of approach used for data analysis, type of biological sample analysed, source of biological sample analysed and area of application), as well as partnership activity (in terms of number of partnerships and type of agreement).
- Elaborate profiles of various prominent players that are currently engaged in offering metabolomics services. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), details related to its recent developments and an informed future outlook.
- An analysis of the partnerships that have been inked between several stakeholders engaged in providing metabolomic services, during the period 2014-2022, covering research agreements, R&D agreements, commercialization agreements, metabolomics data sharing agreements, acquisitions, service alliances, product development agreements and other agreements.
- An insightful framework depicting the implementation of several advanced tools and technologies, such as artificial intelligence, big data analytics, block chain, cloud computing, deep learning, machine learning and quantum computing, at different stages of a metabolomics study, which can assist service providers in addressing existing unmet needs. Further, it provides a detailed analysis on ease of implementation and associated risk in integrating above-mentioned technologies, based on the trends highlighted in published literature and patents.
- One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for metabolomics services market in the next 13 years. Additionally, it features market size projections for the metabolomics services market, wherein both the current and upcoming opportunity is segmented across [A] area of application (biomarker discovery, personalized medicine, disease diagnostics, drug discovery and toxicological testing), [B] type of metabolomics service (targeted metabolomics and untargeted metabolomics), [C] type metabolome profiling technique (LC-MS, GC-MS and NMR), [D] type of end user (academic / research institutes, pharma / biotech firms, and CROs) and [E] key geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
- Oliver Schimts (Head of Metabolome Data Science, BASF Metabolome Solutions)
- Manoj Kumar (Indian Representative - Eroth Technologies, biocrates life sciences)
- Bernhard Drotleff (Scientific Officer, European Molecular Biology Laboratory)
- Morten Danielsen (Chief Executive Officer, MS-Omics)
- Gilbert Skorski (Chairman and Chief Executive Officer, Phylogene)
Key Questions Answered
- Who are the leading players engaged in providing metabolomics services?
- Which metabolomics services are most commonly offered by service providers engaged in this market?
- What is the relative competitiveness of metabolomics service providers?
- What types of partnership models are commonly being adopted by stakeholders in this industry?
- What is the likely performance enhancement value upon integrating novel tools / technologies in metabolomics studies?
- Which key market trends and driving factors are likely to impact the growth of the metabolomics services market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Table of Contents
1. PREFACE
3. INTRODUCTION
4. MARKET LANDSCAPE
5. KEY INSIGHTS
6. COMPANY COMPETITIVENESS
7. COMPANY PROFILES
8. PARTNERSHIPS AND COLLABORATIONS
9. VALUE CREATION FRAMEWORK: A STRATEGIC GUIDE TO ADDRESS UNMET NEED IN METABOLOMICS
10. MARKET FORECAST
12. EXECUTIVE INSIGHTS
List Of Figures
List Of Tables
Companies Mentioned
- 1st BASE
- Abramson Cancer Center, Penn Medicine
- Absorption Systems (acquired by Pharmaron)
- Afekta Technologies
- Agilent Technologies
- Albert Einstein College of Medicine
- Analytica Laboratories
- AnGes
- Anti-Doping Laboratory Qatar
- ARC-BIO, Colorado State University
- Arome Science
- AstraZeneca
- Augusta University
- Australian Institute for Bioengineering and Nanotechnology (AIBN)
- Axon Scientific
- AXYS Analytical Services
- AYOXXA
- Barc Lab
- BASF Metabolome Solutions
- Bayer
- Baylor College of Medicine
- BERG
- Beth Israel Deaconess Medical Center
- Beth Israel Deaconess Medical Center (BIDMC)
- BGI Genomics
- biocrates life sciences
- Biomedical Research Core Facilities, University of Michigan
- Biosfer Teslab
- Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles
- BioXenClue
- BioZone
- Boehringer Ingelheim
- Boston University
- BPS Bioscience
- Brigham and Women’s Hospital
- Bristol Myers Squibb
- CD BioSciences
- CECAD, University of Cologne
- Cedars-Sinai
- Center for Iron and Hematology Disorders, University of Utah
- Centre for Cellular and Molecular Platforms (C-CAMP)
- Centre for Omic Sciences (COS)
- Centre for Organismal Studies, Heidelberg University
- Chalmers University of Technology
- Champions Oncology
- Chenomx
- Children's Hospital of Philadelphia
- CHUM Research Center
- CIC bioGUNE Basque Research and Technology Alliance
- Cincinnati Children's Hospital Medical Center
- Clarus Analytical
- Cleveland Clinic Lerner Research Institute
- Cornell Institute of Biotechnology (CIB)
- Creative Bioarray
- Creative Biogene
- Creative Proteomics
- Cytomics
- Dana Faber Cancer Insitute
- Department of Chemistry, University of Oxford
- Diabetes Research Center, Washington University School of Medicine in St. Louis
- DNA Genotek
- DNA Xperts
- Duke Center for Genomic and Computational Biology (GCB)
- Duke-NUS Medical School
- Eremid Research Services
- European Molecular Biology Laboratory (EMBL)
- Evotec
- Faculty of Biology, Ludwig-Maximilians-Universität München
- Firalis
- Fraunhofer ITEM
- Fred Hutchinson Cancer Research Center
- Frontage Laboratories
- Functional Genomics Center Zurich (FGCZ)
- Fundación MEDINA
- Gemini Biosciences
- General Metabolics
- Georgetown Lombardi Comprehensive Cancer Center
- Germans Trias i Pujol Research Institute (IGTP)
- Gillings School of Global Public Health
- Giotto Biotech
- GlaxoSmithKline
- Helmholtz Zentrum München
- HRL Holdings
- HTG Molecular Diagnostics
- Human Longevity
- Human Metabolome Technologies (HMT)
- Humboldt Universität zu Berlin
- Immuron
- Impulse Dynamics
- Indiana Clinical and Translational Sciences Institute (CTSI)
- Inivata
- Institut Pasteur
- Ion Source & Biotechnologies (ISB)
- IRBM
- Irving Institute for Clinical and Translational Research
- ITSI-BIOSCIENCES
- James Hutton Institute
- John Innes Centre
- JUNO Metabolomics
- J-VPD
- Karolinska Institutet
- Leiden University Medical Center
- Li Ka Shing Faculty of Medicine, The University of Hong Kong (HKUMed)
- Lifeasible
- Liquidia Corporation
- M. J. Murdock Metabolomics Laboratory, Washington State University
- Maastricht UMC+
- MachPhy Solutions
- Max Delbrück Center for Molecular Medicine
- Max Planck Institute for Biology of Ageing
- Max Planck Institute for Molecular Genetics (MPI-MG)
- Max Planck Institute for Terrestrial Microbiology
- Max Planck Institute of Immunobiology and Epigenetics
- Mayo Clinic
- MD Anderson Cancer Center
- Medicilon
- Merck
- MetaboHUB
- Metabolite Profiling Core Facility, Whitehead Institute
- Metabolomics Core, North Carolina Diabetes Research Center
- Metabolon
- Metabolytica
- Metabo-Profile
- Metanomics Health
- metaSysX
- Metdia Biotech
- Monash University
- Montreal Heart Institute
- MRC Cancer Unit, University of Cambridge
- MS-Omics
- MtoZ Biolabs
- MTT Lab
- Muses Labs
- MYOS Corporation
- National Biomedical Resource Indigenisation Consortium (NBRIC)
- National Insitute of Allergy and Infectious Diseases
- National Institute on Aging
- Nebraska Center for Biotechnology, University of Nebraska-Lincoln
- Next Trillion Sciences
- North Carolina Biotechnology Center (NCBiotech)
- North Carolina Research Campus (NCRC)
- North Carolina State University
- Northwest Metabolomics Research Cente (NW-MRC)
- North-West University (NWU)
- Northwestern University
- Novelgene Technologies
- Novo Nordisk
- numares
- NuSirt Biopharma
- NYU Langone Health
- OmicsGen LifeSciences
- Oncology Institute of Southern Catalonia
- Osaka University
- Ospedale San Raffaele
- OWL
- Pacific Biosciences
- Parker H
- Perlman School of Medicine, University of Pennsylvania
- Pharmacogenomics Laboratory, Université Laval
- Pharmalegacy Laboratories
- Pharmaron
- PhenoSwitch Bioscience
- Philippine Genome Center (PGC)
- Philips
- Phylogene
- PROMETHEUS METABOLOMICS
- ProSciento
- Proteome Factory
- Quintara Discovery (QDI)
- Redox Biology Centre (RBC), University of Nebraska-Lincoln
- Rosalind and Morris Goodman Cancer Institute, McGill University
- Roy J
- RTI International
- Rubio Laboratorios
- Ruiyi Biotechnology
- Rutgers Cancer Institute
- Sagimet Biosciences
- Sandor Speciality Diagnostics
- Sanyal Biotechnology
- Sartorius
- SCIEX
- Segal Cancer Proteomics Centre (SCPC)
- SGS
- Swedish Metabolomics Centre (SMC), SciLifeLab
- Synbio Technologies
- SYNLAB Group
- System Biosciences (SBI)
- Systems Biology Lab
- Takeda
- Technion-Israel Institute of Technology
- Texas A&M University
- TGA Sciences
- The Arctic University of Norway (UiT)
- The Australian Wine Research Institute (AWRI)
- The Canadian Frailty Network
- The Canadian Longitudinal Study of Aging
- The Center for Innovative Technology (CIT), Vanderbilt University
- The McMaster Institute for Research on Aging
- The Metabolomics Innovation Centre (TMIC)
- The Ohio State University
- The University of Edinburgh
- The University of Melbourne
- The University of Tennessee Health Science Center
- The University of Western Australia
- The Wistar Institute
- Thermo Fischer Scientific
- Thomas Jefferson University
- Turku Bioscience
- U.S. Army Research Institute of Environmental Medicine
- U.S. Department of Veterans Affairs
- UCLA Metabolomics Centre
- University of Alabama at Birmingham
- University of Birmingham
- University of California, Riverside
- University of Cambridge
- University of Colorado Anschutz Medical Campus
- University of Copenhagen
- University of Eastern Piedmont
- University of Florida
- University of Fribourg
- University of Gothenburg
- University of Helsinki
- University of Lausanne
- University of Louisville
- University of Maryland School of Pharmacy
- University of Minnesota
- University of North Texas
- University of Oklahoma
- University of Oslo
- University of Oxford
- University of Texas at Dallas
- University of Victoria (UVic)
- University of Virginia
- University of York
- UT Southwestern Medical Center
- UTMB Mass Spectrometry Facility (MSF)
- Utrecht University
- Vanderbilt University
- Verso Biosciences
- Vienna BioCenter
- W. M. Keck Metabolomics Research Laboratory, Iowa State University
- Wake Forest School of Medicine
- Washington University School of Medicine
- Weill Cornell Medicine
- Weizmann Institute of Science
- West Coast Metabolomics Center
- Xell (acquired by Sartorious)
- X-omics
- Yale University
- Yenepoya Research Center (YRC)
- Zhejiang Dian Diagnostics
Methodology
LOADING...
